Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

What the company is saying

Neuronetics, Inc. announced that it plans to release first quarter 2026 financial and operating results prior to market open on Tuesday, May 5, 2026, and will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The company describes itself as a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and is the maker of NeuroStar® Advanced Therapy. Neuronetics believes that mental health is as important as physical health and describes itself as a global leader in neuroscience, delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is described as a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. Neuronetics sells the NeuroStar Advanced Therapy System and associated treatment sessions to customers and operates Greenbrook TMS Inc. treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. NeuroStar Advanced Therapy is described as the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21.

What the data suggests

The announcement provides the scheduled release date for first quarter 2026 financial and operating results (May 5, 2026) and the time of the related conference call (8:30 a.m. Eastern Time). No revenue, profit, margin, patient volume, or operational metrics are disclosed. There is no information about recent financial performance, growth rates, or period-over-period comparisons. There is no reference to prior financial targets, guidance, or whether such targets have been met or missed.

Analysis

The announcement is primarily a procedural notice about the upcoming release of first quarter 2026 financial results and a related conference call, which is a standard disclosure. However, the narrative includes several promotional statements about Neuronetics, Inc., NeuroStar® Advanced Therapy, and Greenbrook TMS Inc. that are not substantiated with numerical evidence or comparative data. Phrases such as 'global leader,' 'exceptional in-office treatments,' and 'extraordinary results' inflate the perceived impact without supporting metrics. The only realised and verifiable claims are the scheduled timing of the results release and the FDA clearance for NeuroStar Advanced Therapy System. There is no mention of new capital outlays, acquisitions, or long-term projections, and the forward-looking content is limited to the procedural scheduling of the earnings release. The gap between narrative and evidence is moderate, as the promotional language is not matched by disclosed data, but there are no egregious or misleading claims.

Announcement summary

Neuronetics, Inc. announced it plans to release its first quarter 2026 financial and operating results before the market opens on Tuesday, May 5, 2026. The company will host a conference call to review these results at 8:30 a.m. Eastern Time the same day. Neuronetics is a medical technology company focused on neurohealth disorders and is the maker of NeuroStar® Advanced Therapy. The company operates Greenbrook TMS Inc. treatment centers across the United States, offering NeuroStar Advanced Therapy and SPRAVATO® (esketamine) for major depressive disorder and other mental health disorders. NeuroStar Advanced Therapy is described as the leading transcranial magnetic stimulation treatment for MDD in adults and is backed by the largest clinical data set of any TMS treatment system for depression.

Disagree with this article?